The significance of the finding lies in the sheer scale of the problem it addresses. Roughly a quarter of all lung adenocarcinomas carry mutations in the KRAS gene, a well-known oncogene that drives uncontrolled cell proliferation by locking cellular growth circuits into the on position. After decades in which KRAS was considered undruggable, the United States Food and Drug Administration has in recent years approved two inhibitors that specifically target a common mutation known as KRAS-G12C. These drugs represented a genuine milestone for patients whose tumors had stopped responding to other treatments, and they can produce meaningful initial responses. Yet the clinical experience has been sobering: while the inhibitors work in about 35 percent of the patients who receive them, tumors almost invariably develop resistance, and most cases eventually relapse.

Until now, the dominant explanation for that resistance has been genetic. Tumor cells typically reactivate KRAS signaling through secondary mutations that prevent the drug from binding to its target, or by producing additional copies of the KRAS gene so that the sheer abundance of the protein overwhelms the inhibitor. Both routes converge on the same destination: sustained activity of the MAP kinase signaling pathway, the growth-promoting cascade that KRAS normally triggers and that fuels cell division. A 2021 study from researchers at Dana-Farber Cancer Institute, which analyzed tumors from 17 patients with non-small cell lung cancer treated with KRAS-G12C inhibition, identified such secondary resistance mutations in a majority of the patients examined. But that study also contained a puzzle. In two of the patients, the tumors showed no obvious resistance mutations at all. Instead, they had transformed from adenocarcinomas into squamous cell carcinomas, a completely different class of lung tumor.

That observation is more remarkable than it might first appear. Adenocarcinomas and squamous cell carcinomas are both classified as non-small cell lung cancers, the most common form of primary lung cancer, but they are thought to arise from different cells of origin and carry distinct genetic profiles. Adenocarcinomas, the most prevalent subtype, often originate from the surfactant-producing cells that line the lungs, while squamous cell carcinomas arise from the cells lining the central airways. Critically, KRAS mutations are found far more frequently in adenocarcinomas than in squamous cell carcinomas. A tumor that abandons its adenocarcinoma identity for a squamous one is, in effect, walking away from the very dependency that the drug was designed to exploit.

To understand how such a transformation could occur, the MIT team, led by graduate student Carrie Rodriguez and Nicolas Mathey-Andrews PhD ’25, with Professor Tyler Jacks of the Koch Institute for Integrative Cancer Research as senior author, engineered a mouse model of lung cancer carrying the precise mutation targeted by the approved inhibitors. When the researchers treated these mice with a KRAS-G12C inhibitor, they found that tumors which had lost the function of a gene called Nkx2-1 were able to undergo the transition from adenocarcinoma to squamous cell carcinoma. Nkx2-1 normally helps maintain alveolar epithelial identity, acting as a guardian of the lung lineage; when it is lost, the cells appear freed from their original identity and can drift toward an alternative fate.

The researchers also identified a second route into the same destination. Turning on a transcription factor called DeltaNp63, which is overactive in many squamous cell carcinomas, made the adeno-to-squamous transition more likely. A third player, the transcription factor SOX2, also helped stimulate the transition, although it could not initiate the process on its own. Together, these findings sketch a regulatory landscape in which the fate of a lung tumor cell is governed by a balance of lineage-defining factors: loss of the lung identity keeper Nkx2-1 on one side, or overexpression of squamous master regulators such as SOX2 or DeltaNp63 on the other, can tip the cell into a new state.

What makes these transformed tumors so dangerous is what the researchers observed about their signaling. The tumors that underwent the tissue transformation did not acquire the mutations that typically boost KRAS expression in adenocarcinomas. Instead, KRAS signaling was shut off, or at least dampened significantly, rendering the inhibitor irrelevant. The cells no longer require the oncogene the drug was blocking, and the team hypothesizes that they switch on alternative signaling pathways that allow them to keep growing. Identifying those pathways is now a central goal of the ongoing work, because they could reveal targets for new drugs capable of preventing or delaying resistance to KRAS inhibitors.

The clinical implications are considerable. Targeted cancer therapies have transformed outcomes in many tumor types, but their Achilles heel has always been the emergence of resistance, and this study adds an important dimension to how that resistance can arise. If a tumor can escape a drug not by mutating the target but by changing what it fundamentally is, then combination strategies may need to account for lineage plasticity as well as classic genetic escape routes. As Rodriguez notes, the main takeaway is that there appear to be different routes of resistance to KRAS inhibitors, and the field needs to think about how to address them. Monitoring tumors for signs of transformation, and developing agents that block the transition itself, could become essential components of future treatment regimens for the many patients whose lung adenocarcinomas harbor KRAS mutations.

There is also a broader scientific payoff. As Mathey-Andrews points out, the adeno-to-squamous transition is a process that remains poorly understood, and the team was encouraged that their models could capture it in the laboratory. The researchers are now digging deeper into what happens inside tumor cells as they shift into a squamous state, hoping to uncover vulnerabilities that could be exploited therapeutically. Future work aimed at translation will use these models to define the conditions under which histologic transformation occurs and to nominate potential downstream targets for drug development. The study was supported in part by the Koch Institute Support Grant from the National Cancer Institute, a Ruth Kirschstein National Service Research Award, the National Institute of General Medical Sciences, and the Ludwig Center at MIT. For patients facing the prospect of relapse after KRAS-targeted therapy, the study offers both a warning and a roadmap: the escape routes are more varied than once believed, but they are now, for the first time, being mapped.

Subject of Research: Mechanisms of resistance to KRAS inhibitors in lung adenocarcinoma through gene amplification and lineage transformation

Article Title: Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs

Article References: Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: KRAS inhibitors, lung adenocarcinoma, squamous cell carcinoma, drug resistance, lineage plasticity, Nkx2-1, DeltaNp63, SOX2, MAP kinase pathway, KRAS-G12C, targeted therapy, Nature Genetics